Year: 2020

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol^® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

• ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol^® as agreed with U.S. Food and Drug Administration (FDA)
• Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial
• Topline data expected in 2^nd half 2021

LAVAL, Quebec, Nov. 24, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD). Enrollment of the first Phase 3 study is currently underway and has reached 85% of its enrollment goal.

ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3.

Heidelberg – July 23, 2020 – Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today provided a development update on its investigational water-free and preservative-free drug CyclASol®.